Zhang Quan, Wang Miao, Han Chunle, Wen Zhijun, Meng Xiaozhu, Qi Dongli, Wang Na, Du Huanqing, Wang Jianhong, Lu Lu, Ge Xiaohu
Tingo Exosomes Technology Co., Ltd., Tianjin 300301, China.
Tingo Regenerative Medicine Technology Co., Ltd., Tianjin 300301, China.
Vaccines (Basel). 2023 Mar 16;11(3):673. doi: 10.3390/vaccines11030673.
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has presented numerous challenges to global health. Vaccines, including lipid-based nanoparticle mRNA, inactivated virus, and recombined protein, have been used to prevent SARS-CoV-2 infections in clinics and have been immensely helpful in controlling the pandemic. Here, we present and assess an oral mRNA vaccine based on bovine-milk-derived exosomes (milk-exos), which encodes the SARS-CoV-2 receptor-binding domain (RBD) as an immunogen. The results indicate that RBD mRNA delivered by milk-derived exosomes can produce secreted RBD peptides in 293 cells in vitro and stimulates neutralizing antibodies against RBD in mice. These results indicate that SARS-CoV-2 RBD mRNA vaccine loading with bovine-milk-derived exosomes is an easy, cheap, and novel way to introduce immunity against SARS-CoV-2 in vivo. Additionally, it also can work as a new oral delivery system for mRNA.
严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）引发了2019冠状病毒病（COVID-19），给全球健康带来了诸多挑战。包括脂质纳米颗粒信使核糖核酸（mRNA）、灭活病毒和重组蛋白在内的疫苗已在临床上用于预防SARS-CoV-2感染，并在控制疫情方面发挥了巨大作用。在此，我们展示并评估了一种基于牛乳来源外泌体（乳外泌体）的口服mRNA疫苗，该疫苗将SARS-CoV-2受体结合域（RBD）编码为免疫原。结果表明，乳源外泌体递送的RBD mRNA可在体外293细胞中产生分泌型RBD肽，并刺激小鼠产生针对RBD的中和抗体。这些结果表明，装载有牛乳来源外泌体的SARS-CoV-2 RBD mRNA疫苗是一种在体内引入针对SARS-CoV-2免疫力的简便、廉价且新颖的方法。此外，它还可作为一种新的mRNA口服递送系统。
